WO2010059214A4 - Biocompatible biodegradable intraocular implant system - Google Patents

Biocompatible biodegradable intraocular implant system Download PDF

Info

Publication number
WO2010059214A4
WO2010059214A4 PCT/US2009/006195 US2009006195W WO2010059214A4 WO 2010059214 A4 WO2010059214 A4 WO 2010059214A4 US 2009006195 W US2009006195 W US 2009006195W WO 2010059214 A4 WO2010059214 A4 WO 2010059214A4
Authority
WO
WIPO (PCT)
Prior art keywords
intraocular implant
eye
treating
localized region
ocular condition
Prior art date
Application number
PCT/US2009/006195
Other languages
French (fr)
Other versions
WO2010059214A3 (en
WO2010059214A2 (en
Inventor
Kevin H. Cuevas
Original Assignee
Insight Innovations, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09827868.2T priority Critical patent/ES2606491T3/en
Priority to CA2743335A priority patent/CA2743335A1/en
Priority to EP09827868.2A priority patent/EP2364127B1/en
Priority to NZ592645A priority patent/NZ592645A/en
Priority to MX2011005272A priority patent/MX2011005272A/en
Priority to US12/998,652 priority patent/US20110230963A1/en
Priority to AU2009318158A priority patent/AU2009318158B2/en
Application filed by Insight Innovations, Llc filed Critical Insight Innovations, Llc
Publication of WO2010059214A2 publication Critical patent/WO2010059214A2/en
Publication of WO2010059214A3 publication Critical patent/WO2010059214A3/en
Publication of WO2010059214A4 publication Critical patent/WO2010059214A4/en
Priority to US13/136,515 priority patent/US8551167B2/en
Priority to US13/479,178 priority patent/US20120232649A1/en
Priority to US13/944,817 priority patent/US9204961B2/en
Priority to US14/298,318 priority patent/US9855135B2/en
Priority to US14/821,645 priority patent/US9943402B2/en
Priority to US14/961,734 priority patent/US9943404B2/en
Priority to US15/268,861 priority patent/US10548766B2/en
Priority to US15/915,535 priority patent/US20180193135A1/en
Priority to US15/954,180 priority patent/US20180228600A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/15—Implant having one or more holes, e.g. for nutrient transport, for facilitating handling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1602—Corrective lenses for use in addition to the natural lenses of the eyes or for pseudo-phakic eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
    • A61F2002/009—Special surfaces of prostheses, e.g. for improving ingrowth for hindering or preventing attachment of biological tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063—Three-dimensional shapes
    • A61F2230/0065—Three-dimensional shapes toroidal, e.g. ring-shaped, doughnut-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • A61L2300/61—Coatings having two or more layers containing two or more active agents in different layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Abstract

Generally, an intraocular implant and methods for treating an ocular condition. As to certain embodiments, an intraocular biocompatible biodegradable implant (11) which can provide a biocompatible biodegradable material in the form of a flexible membrane (12) containing an active agent (24) which implanted between an intraocular lens (8) and the surface of the posterior capsule (5) of the eye (1)(4) inhibits migration of residual lens epithelial cells after cataract surgery by providing structural or pharmaceutical barriers to reduce posterior capsule (5) opacification of the eye (1)(4).

Claims

AMENDED CLAIMS received by the International Bureau on 13 October 2010 (13.10.2010)
VI. CLAIMS
1. An, wherein the localized region is selected from the group consisting of: i) between the lens and the surface of the posterior capsule; ii) between the lens and the surface of the iris; and iii) overlying the iris intraocular implant, comprising: a) a biocompatible substantially planar circular flexible membrane configured to implant in a localized region inside an eye; and b) an aperture element which communicates between opposed sides of said membrane to provide a passage opening, said passage opening configured to intraocularly align with a visual axis of said eye, thereby providing a line of sight which passes through said passage opening.
2. The intraocular implant of claim 1 , wherein said aperture element defines a generally circular passage opening.
3. The intraocular implant of claim 2, wherein said generally circular passage opening has a diameter in the range of about 1.5 millimeter to about 9 millimeters.
4. The intraocular implant of claim 1, wherein said biocompatible flexible membrane is generated from a polymeric material selected from the group consisting of: polyurethanc, polyisobutylene, ethylene-alpha-olefin copolymer, acrylic polymers, acrylic copolymers, vinyl halide polymer, vinyl halide copolymer, polyvinyl esters, polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatic, polystyrene, ethylene-methyl methacrylatc copolymers, acrylonitrile-styrene copolymers, ABS resins, ethylene-vinyl acetate copolymers, polyamides, Nylon 66, polycaprolactone, alkyd resins, polycarbonates, polyoxycthylenes, polyimides, polyesters, epoxy resins, rayon-triacetate, and cellophane.
5. The intraocular implant of claim I, wherein said membrane comprises a biodegradable membrane.
6. The intraocular implant of claim 5, wherein said membrane is generated from a polymeric material selected from the group consisting of: polylactide polymers (PLA),
39 copolymers of lactic and glycolic acids (PLGA), polylactic acid-polyethylene oxide copolymers, poly(ε-caρrolactone-co-L-lactic acid (PCL-LA), glyciπe/PLA copolymers, PLA copolymers involving polyethylene oxides (PEO), acetylated polyvinyl alcohol (PVA)/polycaprolactone copolymers, hydroxybutyrate-hydroxyvaleratc copolymers, polyesters of aspartic acid and aliphatic diols, poly(alkylene tartrates)/polyurethane copolymers, polyglutamates, biodegradable nonpeptidic polyamides, amino acid polymers, polyanhydride drug carriers such as, but not limited to, poly(sebacic acid) (PSA), aliphatic- aromatic homopolymers, poly(anhydride-co-imides), ρoly(ρhosρhoesters), poly(phosρhazenes), poly(iminocarbonate), crosslinked poly(ortho ester), hydroxylated polyester-urethanes, hydrogels, and methylcellulose.
7. The intraocular implant of claim 5, further comprising at least one active agent dispersed in said membrane releasable in sufficient amounts to treat an ocular condition.
8. The intraocular implant of claim 7, wherein said at least one active agent is selected from the group consisting of: antibiotic agents, antibacterial agents, antiviral agents, antiglaucoma agents, antiallergenic agents, antiinflammatory agents, antiproliferative agents, immune system modifying agents, anticancer agents, antisense agents, antimytotic agents, myotic agents, ace inhibitors, endogenous cytokines, basement membrane influencing agents, endothelial cell growth agents, epithelial cell growth agents, adrenergic agonists, adrenergic blockers, cholinergic agonists, cholinergic blockers, aldose reductase inhibitors, analgesics, anesthetics, antiallergics, antihypertensives, pressors, anttbacterials, antivirals, antifungals, antiprotozoals, anti-infectives, antitumor agents, antimetabolites, daunomycin, antiangiogenic agents, tyrosine kinase inhibitors, aminoglycosides, gentamicin, kanamycin, neomycin, vancomycin, amphenicols, chloramphenicol, cephalosporins, cefazolin HCl, penicillins, ampicillin, penicillin, carbenicillin, oxycillin, methicillin, lincosamides, lincomycin, polypeptide antibiotics, polymixin, bacitracin, tetracycline, minocycline, doxycycline, quinolones, ciprofloxain, moxifloxacin, gatifloxacin, levofloxacin, sulfonamides, chloramine T, sulfones, sulfanilic acid, acyclovir, gancyclovir, vidarabine, azidothymidine, dideoxyinosine, dideoxycytosine, dexamethasone, epinephrine, isoflurphate, adriamycin, bleomycin, mitomycin, ara-C, actiπomycin D, scopolamin, analgesics, codeine, morphine, keterolac, naproxen, anesthetics, lidocaine, beta.-adrenergic blocker, beta. -adrenergic agonist, ephidrine, epinephrine, aldose reductase inhibitor, epalrestat, ponalrestat, sorbinil, tolrestat,
40 cromolyn, beclomethasone, dexamethasone, flunisolide, colchicine, anihelminthic agents, ivermectin, suramin sodium, antiamebic agents, chloroquine, chlortetracycline, antifungal agents, amphotericin, antiangiogenesis compounds, anecortave acetate, retinoids, tazarotene, brimonidine alphagan, Alphagaπ P, acetozolamide, bimatoprost, lumigan, timolol, mebefunolol, memantine, alρha-2 adrenergic receptor agonists, 2-methoxyestradiol, antineoplastic agents, vinblastine, vincristine, alpha interferon, beta interferon, gamma interferon, antimetabolites, folic acid analogs, purine analogs, pyrimidine analogs, immunosuppressant agents, azathiprine, cyclosporine, mizoribine, miotic agents, carbachol, mydriatic agents, atropine, protease inhibitors, aprotinin, camostat, gabexate, vasodilators, bradykinin, epidermal growth factor, basic fibroblast growth factor, nerve growth factors, steroidal anti-inflammatory agents, 21 -acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, parametliasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednivat, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, vascular endothelial growth factor inhibitors, bevacizumab, ranibisumab, pegatanib, transforming growth factor inhibitors, and fibroblast growth factor inhibitors.
9. The intraocular implant of any one of claims 1, 5 or 7, further comprising an amount of non-active agent dispersed in said membrane.
10. The intraocular implant of claim 9, wherein said amount of non-active agent is selected from the group consisting of: sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and pheπylethyl alcohol, sodium carbonate, sodium
41 borate, sodium phosphate, sodium acetate, sodium bicarbonate, sodium chloride and potassium chloride.
11. The intraocular implant of claim 5, wherein said membrane comprises a first membrane layer coupled to a second membrane layer.
12. The intraocular implant of claim 11, wherein said first membrane layer and said second flexible membrane layer comprise different polymeric materials.
13. The intraocular implant of claim 12, wherein said first flexible membrane layer biodegrades at a different rate than said second membrane layer.
14. The intraocular implant of claim 13, wherein at least one of said first membrane layer and said second membrane layer include an active agent.
15. The intraocular implant of claim 14, wherein said first membrane layer and said second membrane layer each contain said active agent, and wherein said active agent contained in said first membrane layer is different than said active agent contained in said second membrane layer.
16. The intraocular implant of claim 5, wherein said membrane comprises a first annular zone and a second annular zone.
17. The intraocular implant of claim 16, wherein said first annular zone biodegrades at a different rate than said second annular zone.
18. The intraocular implant of claim 17, wherein at least one of said first annular zone and said second annular zone contain an active agent.
19. The intraocular implant of claim 18, wherein said first annular zone and said second annular zone each contain an active agent, and wherein said active agent contained in said first annular zone is different than said active agent contained in said second annular zone.
20. The intraocular implant of claim 5, further comprising an outer boundary of said membrane which defines a generally circular area.
21. The intraocular implant of claim 20, further comprising a plurality of radial slit elements each originating at said aperture element extending radially outward toward said outer boundary.
22. The intraocular implant of claim 20, further comprising a plurality of radial slit elements each originating at said outer boundary extending radially inward toward said aperture element.
23. The intraocular implant of claim 20, further comprising a plurality of radial capillaries which communicate between said outer boundary and said aperture element, said plurality of radial capillaries configured to allow fluid within said eye to circulate between said first side of said intraocular implant and a surface of said localized region inside said eye.
24. The intraocular implant of claim 20, further comprising a plurality of outer boundary recess elements which periodically interrupt the outer boundary.
25. The intraocular implant of claim 5, further comprising a plurality of corrugate elements disposed in generally linear parallel relation to provide undulations in said biodegradable biocompatible flexible membrane, said plurality of corrugate elements configured to allow fluid within said eye to circulate between said first side of said intraocular implant and said surface of said posterior capsule of said eye.
26. The intraocular implant of claim 5, further comprising a plurality of perforation elements which communicate between opposed sides of said membrane.
27. The intraocular implant of claim 5, further comprising a patterned surface element coupled to said membrane, said pattern surface element configured to reduce travel of said intraocular implant within said localized region of said eye.
43
31. The intraocular implant of claim 5, further comprising an amount of alkylphosphocholine dispersed in said membrane releasable in amounts sufficient to provide a concentration of alkylphosphochotine in said localized region in a range of about 0.5 mM to about 1.5 mM for about five days.
32. The intraocular implant of claim 5, further comprising an amount of mitomycin-C dispersed in said membrane releasable in amounts sufficient to provide a concentration of mitomycin-C in said localized region of about 0.04 mg/mL for a period of about five days.
33. A method of treating an ocular condition, comprising the steps of intraocularly locating the intraocular implant of claim 1.
34. The method of treating an ocular condition of claim 33, further comprising the steps of: a) locating said intraocular implant in a localized region inside an eye selected from the group consisting of: i) between the lens and the surface of the posterior capsule; ii) between the lens and the surface of the iris; and iii) overlying the iris; and b) aligning a passage opening defined by an aperture element of said intraocular implant with the visual axis of said eye; and c) providing a line of sight which passes through said passage opening of said aperture element of said intraocular implant implanted in said localized region inside said eye.
36. The method of treating an ocular condition of claim 34, further comprising the step of inhibiting migration of target cells into said localized region of said eye.
38. The method of treating an ocular condition of claim 36, further comprising the step of structurally inhibiting migration of said target cells into said localized region of said posterior capsule of said eye by location of said intraocular implant proximate said surface of said posterior capsule of said eye.
44
39. The method of treating an ocular condition of claim 38, wherein said step of inhibiting migration of target cells into said localized region of said posterior capsule of said eye by location of said intraocular implant proximate said surface of said posterior capsule of said eye comprises the step of pharmaceutically inhibiting migration of said target cells into said localized region of said posterior capsule of said eye by location of said intraocular implant proximate said surface of said posterior capsule of said eye.
40. The method of treating an ocular condition of claim 39, wherein said step of pharmaceutically inhibiting migration of said target cells into said localized region of said posterior capsule of said eye by location of said intraocular implant proximate said surface of said posterior capsule of the eye comprises the steps of: a) releasing an amount of an active agent from said intraocular implant into said localized region sufficient to inhibit migration of said target cells; b) contacting said target cells with said active agent released from said intraocular implant; and c) inhibiting migration of said target cells in to said localized region of the posterior capsule of the eye.
41. The method of treating an ocular condition of any one of claims 36, 38, 39 or 40, wherein said target cells comprise residual lens epithelial cells.
42. The method of treating an ocular condition of claim 41, further comprising the step of killing said residual lens epithelial cells.
44. The method of treating an ocular condition of claim 42, further comprising the steps of a) biodegrading said intraocular implant within said localized region of said posterior capsule of said eye over a duration of time; and b) reabsorbing resultant materials of biodegrading said intraocular implant within said localized region of said posterior capsule of said eye.
45. The method of treating an ocular condition of claim 44, further comprising the steps of:
45 a) providing a plurality of radial slit elements each of which originate at said aperture element extending radially outward toward an outer boundary of said intraocular implant; and b) biasing rate at which said intraocular implant biodegrades, wherein said intraocular implant biodegrades at a greater rate proximate said aperture element and at a lesser rate proximate said outer boundary, thereby biodegrading said intraocular implant directionally from said aperture element toward an outer boundary.
46. The method of treating an ocular condition of claim 44, further comprising the steps of: a) providing a first membrane layer of said intraocular implant; and b) providing a second membrane layer of said intraocular implant, and wherein said first membrane layer of said intraocular implant biodegrades a greater rate than said second membrane layer, thereby biodegrading said intraocular implant directionally from said first membrane layer toward said second membrane layer.
47. The method of treating an ocular condition of claim 44, further comprising the steps of: a) providing a first annular zone of said intraocular implant; and b) providing a second annular zone of said intraocular implant, and wherein said first annular zone of said intraocular implant biodegrades a greater rate than said second annular zone, thereby biodegrading said intraocular implant directionally from first annular zone toward said second annular zone.
48. The method of treating an ocular condition of claim 47, farther comprising the step of providing a plurality of perforation elements which communicate between opposed sides of said membrane thereby increasing the rate at which said intraocular implant degrades.
49. The method of treating an ocular condition of claim 46, wherein said step of releasing an effective amount of an active agent from said intraocular implant into said localized region to inhibit migration of said target cells comprises the steps of: a) releasing a first active agent from a first membrane layer of said intraocular implant; and
46 b) releasing a second active agent from a second membrane layer of said intraocular implant.
50. The method of treating an ocular condition of claim 47, wherein said step of releasing an effective amount of an active agent from said intraocular implant into said localized region to inhibit migration of said target cells comprises the steps of: a) releasing a first active agent from a first annular zone of said intraocular implant; and b) releasing a second active agent from a second annular zone of said intraocular implant.
51. The method of treating an ocular condition of claim 34, further comprising the step of providing a plurality of corrugate elements in said membrane, said corrugate elements configured to allow fluid within said eye to circulate between said first side of said intraocular implant and a surface of said localized region of said eye.
52. The method of treating an ocular condition of claim 34, further comprising the step of providing a plurality of radial capillaries which communicate between said outer boundary and said aperture element, said plurality of radial capillaries configured to allow fluid within said eye to circulate between said first side of said intraocular implant and said surface of said localized region of said eye.
53. The method of treating an ocular condition of claim 34, further comprising the step of engaging a patterned surface element of said first surface of said membrane with said surface of said posterior capsule, thereby reducing travel of said intraocular implant within said localized region of said eye.
54. The method of treating an ocular condition of claim 40, wherein said step of releasing an effective amount of an active agent from said intraocular implant into said localized region to inhibit migration of said target cells comprises the step of releasing an amount of alkylphosphocholine within said localized region of said posterior capsule sufficient to provide a concentration of alkylphosphocholine in the range of about 0.5 mM to about 1.5 mM for about five days.
47
55. The method of treating an ocular condition of claim 40, wherein said step of releasing an effective amount of an active agent from said intraocular implant into said localized region to inhibit migration of said target cells comprises the step of releasing an amount of mitomycin-C within said localized region of said posterior capsule sufficient to provide a concentration of mitomycin-C of about 0.04 mg/mL for a period of about five days.
56. The method of treating an ocular condition of claim 34, wherein said step of locating said intraocular implant in a localized region inside an eye comprises the step of locating said intraocular implant inside a ciliary sulcus of said eye between a lens and a surface of an iris.
57. The method of treating an ocular condition of claim 34, wherein said step of locating said intraocular implant in a localized region inside an eye comprises the step of locating said intraocular implant inside an anterior chamber of said eye overlaying a surface of an iris.
58. The method of treating an ocular condition of any one of claims 56 or 57, further comprising the step of releasing a therapeutically effective amount of an active agent from said intraocular implant into said localized region.
59. The method of treating an ocular condition of claim 58, further comprising the steps of: a) biodegrading said intraocular implant within said localized region of said eye over a duration of time; and b) reabsorbing resultant materials of biodegrading said intraocular implant within said localized region of said eye.
60. The method of treating an ocular condition of claim 59, further comprising the steps of: a) providing a plurality of radial slit elements each of which originate at said aperture element extending radially outward toward an outer boundary of said intraocular implant; and b) biasing rate at which said intraocular implant biodegrades, wherein said intraocular implant biodegrades at a greater rate proximate said aperture element and at a
48 lesser rate proximate said outer boundary, thereby biodegrading said intraocular implant directionally from said aperture element toward an outer boundary.
61. The method of treating an ocular condition of claim 59, further comprising the steps of: a) providing a first membrane layer of said intraocular implant; and b) providing a second membrane layer of said intraocular implant, and wherein said first membrane layer of said intraocular implant biodegrades a greater rate than said second membrane layer, thereby biodegrading said intraocular implant directionally from said first flexible membrane layer toward said second flexible membrane layer.
62. The method of treating an ocular condition of claim 59, further comprising the steps of: a) providing a first annular zone of said intraocular implant; and b) providing a second annular zone of said intraocular implant, and wherein said first annular zone of said intraocular implant biodegrades a greater rate than said second annular zone, thereby biodegrading said intraocular implant directionally from first annular zone toward said second annular zone.
63. The method of treating an ocular condition of claim 59, further comprising the step of providing a plurality of perforation elements which communicate between opposed sides of said biodegradable biocompatible membrane thereby increasing the rate at which said intraocular implant degrades.
64. The method of treating an ocular condition of claim 61, wherein said step of releasing a therapeutically effective amount of an active agent from said intraocular implant into said localized region comprises the steps of: a) releasing a first active agent from a first membrane layer of said intraocular implant; and b) releasing a second active agent from a second membrane layer of said intraocular implant.
49
65. The method of treating an ocular condition of claim 62, wherein said step of releasing a therapeutically effective amount of an active agent from said intraocular implant into said localized region comprises the steps of: a) releasing a first active agent from a first annular zone of said intraocular implant; and b) releasing a second active agent from a second annular zone of said intraocular implant.
66. The method of treating an ocular condition of claim 59, further comprising the step of providing a plurality of corrugate elements in said membrane, said corrugate elements configured to allow fluid within said eye to circulate between said first side of said intraocular implant and said surface of said posterior capsule of said eye.
67. The method of treating an ocular condition of claim 59, further comprising the step of providing a plurality of radial capillaries which communicate between said outer boundary and said aperture element, said plurality of radial capillaries configured to allow fluid within said eye to circulate between said first side of said intraocular implant and said surface of said posterior capsule of said eye.
68. The method of treating an ocular condition of claim 59, further comprising the step of engaging a patterned surface element of said first surface of said membrane with said surface of said posterior capsule, thereby reducing travel of said intraocular implant within said localized region of said eye.
50
PCT/US2009/006195 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system WO2010059214A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA2743335A CA2743335A1 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
EP09827868.2A EP2364127B1 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
NZ592645A NZ592645A (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
MX2011005272A MX2011005272A (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system.
US12/998,652 US20110230963A1 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
ES09827868.2T ES2606491T3 (en) 2008-11-20 2009-11-19 Biodegradable and biocompatible intraocular implant system
AU2009318158A AU2009318158B2 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
US13/136,515 US8551167B2 (en) 2008-11-20 2011-08-02 Intraocular implant cell migration inhibition system
US13/479,178 US20120232649A1 (en) 2008-11-20 2012-05-23 Intraocular Lens Cell Migration Inhibition System
US13/944,817 US9204961B2 (en) 2008-11-20 2013-07-17 Method of implanting an intraocular device to inhibit cell migration and opacification of the posterior capsule of the eye
US14/298,318 US9855135B2 (en) 2008-11-20 2014-06-06 Cell migration inhibition system
US14/821,645 US9943402B2 (en) 2008-11-20 2015-08-07 Micropatterned intraocular implant
US14/961,734 US9943404B2 (en) 2008-11-20 2015-12-07 Intraocular cell migration inhibition system
US15/268,861 US10548766B2 (en) 2008-11-20 2016-09-19 Biocompatible biodegradable intraocular implant system
US15/915,535 US20180193135A1 (en) 2008-11-20 2018-03-08 Intraocular Cell Migration Inhibition System
US15/954,180 US20180228600A1 (en) 2008-11-20 2018-04-16 Micropatterned intraocular implants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19967408P 2008-11-20 2008-11-20
US61/199,674 2008-11-20
US27056709P 2009-07-10 2009-07-10
US61/270,567 2009-07-10

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/998,652 A-371-Of-International US20110230963A1 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system
US13/136,515 Continuation-In-Part US8551167B2 (en) 2008-11-20 2011-08-02 Intraocular implant cell migration inhibition system
US15/268,861 Continuation US10548766B2 (en) 2008-11-20 2016-09-19 Biocompatible biodegradable intraocular implant system

Publications (3)

Publication Number Publication Date
WO2010059214A2 WO2010059214A2 (en) 2010-05-27
WO2010059214A3 WO2010059214A3 (en) 2010-10-14
WO2010059214A4 true WO2010059214A4 (en) 2010-12-02

Family

ID=42198717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/006195 WO2010059214A2 (en) 2008-11-20 2009-11-19 Biocompatible biodegradable intraocular implant system

Country Status (9)

Country Link
US (2) US20110230963A1 (en)
EP (2) EP2364127B1 (en)
AU (2) AU2009318158B2 (en)
CA (1) CA2743335A1 (en)
ES (1) ES2606491T3 (en)
HU (1) HUE031062T2 (en)
MX (1) MX2011005272A (en)
NZ (1) NZ592645A (en)
WO (1) WO2010059214A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9675443B2 (en) 2009-09-10 2017-06-13 Johnson & Johnson Vision Care, Inc. Energized ophthalmic lens including stacked integrated components
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
CA2743335A1 (en) 2008-11-20 2010-05-27 Insight Innovations, Llc Biocompatible biodegradable intraocular implant system
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
DE102009007853A1 (en) * 2009-02-06 2010-08-12 LMU Ludwig-Maximilians-Universität München Intraocular lenses treated with alkylphosphocholines for pharmacological after-stage prophylaxis
US9492272B2 (en) 2009-08-13 2016-11-15 Acufocus, Inc. Masked intraocular implants and lenses
BR112012008079A2 (en) 2009-08-13 2016-03-01 Acufocus Inc corneal graft with nutrient transport structures
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
WO2012021108A1 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A biodegradable ocular implant
SG187761A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A glaucoma valve, a casing for containing a glaucoma valve, and a glaucoma drainage device comprising the valve and/or the casing
US8950862B2 (en) 2011-02-28 2015-02-10 Johnson & Johnson Vision Care, Inc. Methods and apparatus for an ophthalmic lens with functional insert layers
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9233513B2 (en) 2011-03-18 2016-01-12 Johnson & Johnson Vision Care, Inc. Apparatus for manufacturing stacked integrated component media inserts for ophthalmic devices
US9110310B2 (en) 2011-03-18 2015-08-18 Johnson & Johnson Vision Care, Inc. Multiple energization elements in stacked integrated component devices
US9698129B2 (en) 2011-03-18 2017-07-04 Johnson & Johnson Vision Care, Inc. Stacked integrated component devices with energization
US9195075B2 (en) 2011-03-21 2015-11-24 Johnson & Johnson Vision Care, Inc. Full rings for a functionalized layer insert of an ophthalmic lens
US9102111B2 (en) * 2011-03-21 2015-08-11 Johnson & Johnson Vision Care, Inc. Method of forming a functionalized insert with segmented ring layers for an ophthalmic lens
US9804418B2 (en) 2011-03-21 2017-10-31 Johnson & Johnson Vision Care, Inc. Methods and apparatus for functional insert with power layer
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
US9134546B2 (en) 2012-02-22 2015-09-15 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with segmented ring layers in a functionalized insert
WO2013176982A1 (en) * 2012-05-23 2013-11-28 Insight Innovations, Llc Intraocular lens cell migration inhibition system
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
EP2787040B1 (en) 2013-04-04 2016-02-03 Instituto Tecnológico Del Embalaje, Transporte Y Logistica Itene Composition for preparing a nanostructured biodegradable polymeric material, the obtained material and uses thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
WO2016081493A1 (en) 2014-11-19 2016-05-26 Acufocus, Inc. Fracturable mask for treating presbyopia
US20160287380A1 (en) * 2015-03-30 2016-10-06 Wendian Shi Fluid-filled implantable structures with internal surface-modifying components and related methods
US9948786B2 (en) 2015-04-17 2018-04-17 Cisco Technology, Inc. Handling conferences using highly-distributed agents
WO2017062316A1 (en) 2015-10-05 2017-04-13 Acufocus, Inc. Methods of molding intraocular lenses
CN108348329B (en) * 2015-11-09 2021-07-02 Hoya株式会社 Optical devices with partial or incomplete lenses and associated methods
EP3384342B1 (en) 2015-11-24 2021-08-25 AcuFocus, Inc. Toric small aperture intraocular lens with extended depth of focus
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
CN110337296A (en) * 2016-12-27 2019-10-15 犹他大学研究基金会 Intraocular drug delivery device and correlation technique
BR102017013337A2 (en) * 2017-06-20 2019-01-15 Fundação Ezequiel Dias ocular drug delivery device, bevacizumab-containing polymeric nanofibers and process for obtaining
US11364110B2 (en) 2018-05-09 2022-06-21 Acufocus, Inc. Intraocular implant with removable optic
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
CN110506634B (en) * 2019-09-29 2022-07-05 上海市农业科学院 Iris chemical mutagenesis dose screening method
CN111728767A (en) * 2020-04-24 2020-10-02 海南省眼科医院(中山大学中山眼科中心海南眼科医院) Corneal endothelium protective glasses and application thereof
CN115364280B (en) * 2021-12-15 2023-08-18 郑州大学第一附属医院 Drug sustained-release intraocular lens and preparation method thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444217A (en) * 1891-01-06 Bradley allan fisks
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3794414A (en) 1972-05-12 1974-02-26 Jessen Inc Wesley Multiple focal contact lens
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4124905A (en) 1976-10-29 1978-11-14 Bausch & Lomb Incorporated Artificial intraocular lens system
US4441217A (en) * 1981-12-21 1984-04-10 Cozean Jr Charles H Intraocular lenses
US4624669A (en) * 1984-09-26 1986-11-25 Surgidev Corporation Corneal inlay with holes
SE8501022L (en) * 1985-03-01 1986-09-02 Pharmacia Ab FORMAT CREATES AND PROCEDURES FOR ITS PREPARATION
SE8505518D0 (en) * 1985-11-22 1985-11-22 Swedish Graft Tech Ab IMPLANTATION LENS, PROCEDURE FOR PREPARING THEREOF AND APPARATUS FOR CARRYING OUT THE PROCEDURE
US5282851A (en) 1987-07-07 1994-02-01 Jacob Labarre Jean Intraocular prostheses
US4865601A (en) * 1987-07-07 1989-09-12 Caldwell Delmar R Intraocular prostheses
US4808181A (en) * 1987-08-07 1989-02-28 Kelman Charles D Intraocular lens having roughened surface area
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
FR2668922A1 (en) 1990-11-14 1992-05-15 Franceschi Francois CRYSTALLINE IMPLANT OF POSTERIOR CHAMBER.
KR0185215B1 (en) * 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
EP0507292B1 (en) 1991-04-04 1997-07-02 Menicon Co., Ltd. Device for inhibiting aftercataract
EP0567627A4 (en) 1991-11-14 1994-06-22 Stanley Poler Secondary eye growth impeding device and method
US5405385A (en) * 1992-04-02 1995-04-11 Clemson University Intraocular lens with integrated means of fixation
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
JP2789983B2 (en) * 1993-01-28 1998-08-27 信越半導体株式会社 Machining error correction device
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5593438A (en) 1995-01-20 1997-01-14 Akhavi; David S. Intraocular lens with metallic coatings for preventing secondary cataracts
US5628795A (en) 1995-03-15 1997-05-13 Langerman David W Spare parts for use in ophthalmic surgical procedures
US5549670A (en) * 1995-05-09 1996-08-27 Allergan, Inc. IOL for reducing secondary opacification
US5693094A (en) * 1995-05-09 1997-12-02 Allergan IOL for reducing secondary opacification
US5800533A (en) 1996-03-18 1998-09-01 Harry C. Eggleston Adjustable intraocular lens implant with magnetic adjustment facilities
US20020128710A1 (en) 1996-03-18 2002-09-12 Eggleston Harry C. Modular intraocular implant
US6399693B1 (en) 1997-10-23 2002-06-04 Univ. Of Florida Research Foundation Bioactive composites comprising silane functionalized polyaryl polymers
US6667368B1 (en) 1997-10-23 2003-12-23 University Of Florida Research Foundation Amino acid functionalized polymers for graft copolymerizations
US7169853B2 (en) 1997-10-23 2007-01-30 University Of Florida Research Foundation, Inc. Polyamide graft copolymers
US6884262B2 (en) * 1998-05-29 2005-04-26 Advanced Medical Optics, Inc. Enhanced intraocular lens for reducing glare
US20020010510A1 (en) * 1998-11-04 2002-01-24 Thomas A. Silvestrini Variable modulus corneal implant and fabrication methods
WO2000052516A2 (en) * 1999-03-01 2000-09-08 Boston Innovative Optics, Inc. System and method for increasing the depth of focus of the human eye
DE50013494D1 (en) 1999-12-14 2006-11-02 Boehm Hans Georg Focusable intraocular lens
FR2804860B1 (en) 2000-02-16 2002-04-12 Humanoptics Ag ACCOMODATIVE CRYSTALLINE IMPLANT
US6797004B1 (en) 2000-03-02 2004-09-28 Advanced Medical Optics, Inc. Holders for intraocular lenses
US6551354B1 (en) 2000-03-09 2003-04-22 Advanced Medical Optics, Inc. Accommodating intraocular lens
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7645299B2 (en) * 2001-05-11 2010-01-12 Koziol Jeffrey E Intracorneal lens system having connected lenses
US6524340B2 (en) 2001-05-23 2003-02-25 Henry M. Israel Accommodating intraocular lens assembly
US6884263B2 (en) 2001-07-17 2005-04-26 Medennium, Inc. Accommodative intraocular lens
FR2831423B1 (en) * 2001-10-31 2004-10-15 Bausch & Lomb INTRAOCULAR LENSES PROVIDED WITH ANGULAR EDGES IN ORDER TO AVOID POSTERIOR CAPSULAR OPACIFICATION
FR2832920B1 (en) 2001-11-30 2004-10-01 Visional NEW ACCOMODATIVE INTRAOCULAR IMPLANT
AU2003210534A1 (en) * 2002-01-14 2003-07-30 Advanced Medical Optics, Inc. Accommodating intraocular lens with integral capsular bag ring
US7150759B2 (en) 2002-01-14 2006-12-19 Advanced Medical Optics, Inc. Multi-mechanistic accommodating intraocular lenses
CA2473355C (en) * 2002-01-18 2012-01-03 Michael E. Snyder Sustained release ophthalmological device and method of making and using the same
US6972033B2 (en) 2002-08-26 2005-12-06 Advanced Medical Optics, Inc. Accommodating intraocular lens assembly with multi-functional capsular bag ring
EP1402851B1 (en) * 2002-09-24 2008-06-04 Cesar C. Dr. Carriazo Implant for altering the iris color
US6932839B1 (en) * 2002-11-27 2005-08-23 William Kamerling Intraocular lens assembly and method
FR2849592B1 (en) * 2003-01-08 2005-03-25 Ioltechnologie Production CAPSULAR RING, METHOD OF MANUFACTURING CAPSULAR RING AND CAPSULAR RING ASSEMBLY AND INTRAOCULAR LENS
US6616691B1 (en) * 2003-01-10 2003-09-09 Alcon, Inc. Accommodative intraocular lens
US7238201B2 (en) 2003-02-13 2007-07-03 Visiogen, Inc. Accommodating intraocular lens system with enhanced range of motion
US7029497B2 (en) * 2003-05-21 2006-04-18 Alcon, Inc. Accommodative intraocular lens
US7628810B2 (en) * 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050131535A1 (en) 2003-12-15 2005-06-16 Randall Woods Intraocular lens implant having posterior bendable optic
WO2006028491A1 (en) 2004-02-13 2006-03-16 University Of Florida Biocides based on silanol terminated silanes and siloxanes
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US7117807B2 (en) * 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
US7143709B2 (en) * 2004-02-17 2006-12-05 University Of Florida Research Foundation, Inc. Surface topography for non-toxic bioadhesion control
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7806929B2 (en) * 2004-08-27 2010-10-05 Brown David C Intracapsular pseudophakic device
US7435258B2 (en) * 2004-09-17 2008-10-14 Blake Larry W Accommodating intraocular lens device
US8216308B2 (en) 2004-09-17 2012-07-10 Tekia, Inc. Accommodating artificial ocular lens (AAOL) device
US7491350B2 (en) * 2004-12-01 2009-02-17 Acufocus, Inc. Method of making an ocular implant
US7976577B2 (en) 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
US20070083260A1 (en) * 2005-10-07 2007-04-12 Michael Colvard Intraocular lens spacer for cataract surgery
JP5390862B2 (en) 2006-01-17 2014-01-15 ミナス， セオドア コロネオ， Sac implant for maintaining the shape and / or position of the opening formed by capsulotomy
US8568478B2 (en) * 2006-09-21 2013-10-29 Abbott Medical Optics Inc. Intraocular lenses for managing glare, adhesion, and cell migration
US20080077238A1 (en) * 2006-09-21 2008-03-27 Advanced Medical Optics, Inc. Intraocular lenses for managing glare, adhesion, and cell migration
US8608799B2 (en) * 2007-01-24 2013-12-17 Tekia, Inc. Umbrella-shaped accommodating artificial ocular lens (AAOL) device
KR100843454B1 (en) 2007-03-08 2008-07-03 박경진 Supporter for intraocular lens
US8740978B2 (en) * 2007-08-27 2014-06-03 Amo Regional Holdings Intraocular lens having extended depth of focus
BRPI0820209A2 (en) 2007-11-14 2015-06-16 Alcon Inc Intraocular lens
US8337552B2 (en) * 2008-07-15 2012-12-25 Kowa Company, Ltd. Intraocular lens and manufacturing method thereof
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
CA2743335A1 (en) * 2008-11-20 2010-05-27 Insight Innovations, Llc Biocompatible biodegradable intraocular implant system
US9078744B2 (en) * 2009-02-11 2015-07-14 Novartis Ag Single optic accommodative intraocular lens system
US9492272B2 (en) 2009-08-13 2016-11-15 Acufocus, Inc. Masked intraocular implants and lenses
US8308800B2 (en) * 2010-04-09 2012-11-13 Chu Milton W Intraocular lenses with high contrast haptics, materials, and methods
US8197540B2 (en) * 2010-04-26 2012-06-12 Stellar Devices Llc Ocular implant iris diaphragm
CN102883682A (en) 2010-04-27 2013-01-16 雷恩斯根公司 Accommodating intraocular lens device
US20110313521A1 (en) 2010-06-21 2011-12-22 Angelopoulos Robert D Intraocular rings and associated systems and methods
WO2012031201A2 (en) * 2010-09-03 2012-03-08 Massachusetts Institute Of Technology Fabrication of anti-fouling surfaces comprising a micro- or nano-patterned coating
US20130153612A1 (en) * 2011-12-16 2013-06-20 Magna International Inc. Aerodynamic Underbody Spare Tire Cover
US10028824B2 (en) * 2012-01-24 2018-07-24 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US11077270B2 (en) 2014-08-07 2021-08-03 University Of Florida Research Foundation, Inc. Patterns for flow control and bioadhesion control

Also Published As

Publication number Publication date
AU2016202368A1 (en) 2016-05-05
EP2364127A4 (en) 2013-04-03
US20110230963A1 (en) 2011-09-22
CA2743335A1 (en) 2010-05-27
HUE031062T2 (en) 2017-06-28
EP3127509A1 (en) 2017-02-08
ES2606491T3 (en) 2017-03-24
WO2010059214A3 (en) 2010-10-14
US10548766B2 (en) 2020-02-04
AU2009318158A1 (en) 2010-05-27
MX2011005272A (en) 2011-06-21
US20170000644A1 (en) 2017-01-05
NZ592645A (en) 2013-01-25
EP2364127A2 (en) 2011-09-14
AU2009318158B2 (en) 2016-01-14
AU2009318158A2 (en) 2011-06-09
EP2364127B1 (en) 2016-08-31
WO2010059214A2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
WO2010059214A4 (en) Biocompatible biodegradable intraocular implant system
US9943404B2 (en) Intraocular cell migration inhibition system
US8551167B2 (en) Intraocular implant cell migration inhibition system
AU2015300763B2 (en) Micropatterned intraocular implants
US9943402B2 (en) Micropatterned intraocular implant
CA2222889C (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20180228600A1 (en) Micropatterned intraocular implants
WO2013176982A1 (en) Intraocular lens cell migration inhibition system
NZ621163B2 (en) Intraocular implant cell migration inhibition system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827868

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 592645

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2743335

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009318158

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12998652

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005272

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009827868

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009827868

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009318158

Country of ref document: AU

Date of ref document: 20091119

Kind code of ref document: A